×
About 25,755 results

ALLMedicine™ Acute Lymphoblastic Leukemia Center

Research & Reviews  7,962 results

Rationale and design of Children's Oncology Group (COG) study ACCL20N1CD: financial dis...
https://doi.org/10.1186/s12913-022-08201-0
BMC Health Services Research; Beauchemin M, Santacroce SJ et. al.

Jun 29th, 2022 - The study purpose is to describe trajectories of financial distress for parents of children (ages 1-14.9 years) with newly diagnosed acute lymphoblastic leukemia (ALL). The secondary aim is to identify multilevel factors (child, parent, household,...

Regulatory programs of B-cell activation and germinal center reaction allow B-ALL escap...
https://doi.org/10.1158/2326-6066.CIR-21-0626
Cancer Immunology Research; Im NG, Guillaumet-Adkins A et. al.

Jun 28th, 2022 - Chimeric-antigen receptor (CAR) T-cell therapy has led to tremendous successes in the treatment of B-cell malignancies. However, a large fraction of treated patients relapse, often with disease expressing reduced levels of the target antigen. Here...

Jurkat T cells are immunophenotypically distinct from T-cell acute lymphoblastic leukem...
https://doi.org/10.1080/07357907.2022.2095397
Cancer Investigation; Singh K, Kumari S et. al.

Jun 28th, 2022 - Human leukemic T cells show decreased surface CD5 (sCD5) and increased cytoplasmic CD5 (cCD5). When we examined their expressions in the Jurkat T cells, it showed increased sCD5 and decreased cCD5, which is in sharp contrast with the pattern of CD...

Treatments of Ph-like acute lymphoblastic leukemia: a real-world retrospective analysis...
https://doi.org/10.1080/10428194.2022.2090550
Leukemia & Lymphoma; Xu GF, Liu LM et. al.

Jun 25th, 2022 - Philadelphia chromosome-like acute lymphoblastic leukemia (Ph-like ALL) is a high-risk subtype of ALL. We retrospectively studied 70 cases with Ph-like ALL and here present the largest study of CAR-T cell treatment and haplo-HSCT for this leukemia...

see more →

Guidelines  4 results

Management of adults and children receiving CAR T-cell therapy: 2021 best practice reco...
https://doi.org/10.1016/j.annonc.2021.12.003
Annals of Oncology : Official Journal of the European Soc... Hayden PJ, Roddie C et. al.

Dec 20th, 2021 - Several commercial and academic autologous chimeric antigen receptor T-cell (CAR-T) products targeting CD19 have been approved in Europe for relapsed/refractory B-cell acute lymphoblastic leukemia, high-grade B-cell lymphoma and mantle cell lympho...

Pediatric Acute Lymphoblastic Leukemia, Version 2.2020, NCCN Clinical Practice Guidelin...
https://doi.org/10.6004/jnccn.2020.0001
Journal of the National Comprehensive Cancer Network : JN... Brown P, Inaba H et. al.

Jan 8th, 2020 - Acute lymphoblastic leukemia (ALL) is the most common pediatric malignancy. Advancements in technology that enhance our understanding of the biology of the disease, risk-adapted therapy, and enhanced supportive care have contributed to improved su...

NCCN Guidelines Insights: Acute Lymphoblastic Leukemia, Version 1.2017.
https://doi.org/10.6004/jnccn.2017.0147
Journal of the National Comprehensive Cancer Network : JN... Brown PA, Shah B et. al.

Sep 7th, 2017 - The prognosis for patients with newly diagnosed acute lymphoblastic leukemia (ALL) has improved with the use of more intensive chemotherapy regimens, tyrosine kinase inhibitors, targeted agents, and allogeneic hematopoietic cell transplantation. H...

Role of cytotoxic therapy with hematopoietic stem cell transplantation in the treatment...
https://doi.org/10.1016/j.bbmt.2011.12.585
Biology of Blood and Marrow Transplantation : Journal of ... Oliansky DM, Camitta B et. al.

Jan 3rd, 2012 - Clinical research published since the first evidence-based review on the role of hematopoietic stem cell transplantation (SCT) in the treatment of pediatric acute lymphoblastic leukemia (ALL) is presented and critically evaluated in this update. T...

see more →

Drugs  124 results see all →

Clinicaltrials.gov  930 results

Anti-CD22 Chimeric Receptor T Cells in Pediatric and Young Adults With Recurrent or Refractory CD22-expressing B Cell Malignancies
https://clinicaltrials.gov/ct2/show/NCT02315612

Jun 24th, 2022 - Background: Adoptive cellular therapy with T cells genetically modified using viral-based vectors to express chimeric antigen receptors targeting the CD19 molecule have demonstrated dramatic clinical responses in patients with acute lymphoblastic ...

Phase I Study of Anti-CD22 Chimeric Receptor T Cells in Patients With Relapsed/Refractory Hairy Cell Leukemia and Variant
https://clinicaltrials.gov/ct2/show/NCT04815356

Jun 24th, 2022 - Background Hairy cell leukemia (HCL) is an indolent CD22+ B-cell leukemia comprising 2% of all leukemias. Most cases of HCL respond well to purine analog chemotherapy and harbor BRAF V600E mutation that can be considered for targeted treatment at ...

A Study in Adults With Untreated Acute Lymphoblastic Leukemia
https://clinicaltrials.gov/ct2/show/NCT00136435

Jun 24th, 2022 - This study has four treatment phases: 1) induction, 2) central nervous system therapy, 3) intensification, and 4) continuation. The induction phase lasts one month and eight drugs are used during this phase of treatment. The drugs are administered...

Treatment of Acute Lymphoblastic Leukemia in Children
https://clinicaltrials.gov/ct2/show/NCT00400946

Jun 24th, 2022 - RISK CLASSIFICATION: Patients received were classified into initial risk groups defined as: High Risk (HR) High risk patients had any of the following features: age 10 years and older, a white blood cell count of 50 000 cells per μL or higher, ini...

Vaccinating Children After Chemotherapy
https://clinicaltrials.gov/ct2/show/NCT02447718

Jun 24th, 2022 - Rationale and Aims: Children with acute lymphoblastic leukemia (ALL) have evidence of persistent immunosuppression following chemotherapy and may experience waning of immunity to vaccines received prior to treatment. There is no standard of care i...

see more →

News  1,279 results

CAR T-Cell Therapy May Represent a New Option in Medullary Thyroid Cancer
https://www.onclive.com/view/car-t-cell-therapy-may-represent-a-new-option-in-medullary-thyroid-cancer

May 5th, 2022 - Investigators at the Perelman School of Medicine at the University of Pennsylvania (Penn) have recently initiated a clinical trial evaluating a novel CAR T-cell therapy in an effort to fill an unmet need for systemic treatment for patients with ad...

Donor Stem Cell Infusions Preserve CAR-T Benefit, Improve Survival in B-ALL After Transplant Fail
https://www.medscape.com/viewarticle/973361

May 3rd, 2022 - The study covered in this summary was published on researchsquare.com as a preprint and has not yet been peer reviewed. Key Takeaway Donor hematopoietic stem cell infusions (DSIs) improve the efficacy of CAR T-cell therapy and overall survival for...

Microbiota Modulation Offers Hope of Expanding the Benefits of Immunotherapy
https://www.onclive.com/view/microbiota-modulation-offers-hope-of-expanding-the-benefits-of-immunotherapy

Apr 28th, 2022 - Although the microorganisms colonizing our bodies have long been linked to human health and various disease states, an understanding of the potential impact of the microbiota on cancer has just begun to emerge in the past 20 years. Novel strategie...

CAR NK Cell Therapies Show Preliminary Safety and Efficacy in AML, Non-Hodgkin Lymphoma
https://www.onclive.com/view/car-nk-cell-therapies-show-preliminary-safety-and-efficacy-in-aml-non-hodgkin-lymphoma

Apr 25th, 2022 - The novel allogeneic CAR-engineered natural killer (NK) cell therapies, NKX101 and NKX01, showcased early signs of safety and efficacy when utilized in the treatment of heavily pretreated patients with acute myeloid leukemia (AML) and non-Hodgkin ...

Dr. Akbar on the Efficacy of Monoclonal Antibodies Across Various Trials in R/R ALL
https://www.onclive.com/view/dr-akbar-on-the-efficacy-of-monoclonal-antibodies-across-various-trials-in-r-r-all

Apr 25th, 2022 - Usman Ali Akbar, MD, research coordinator, Division of Infectious Diseases, the University of Louisville, discusses the systematic review of the efficacy of monoclonal antibodies in adult patients with relapsed/refractory acute lymphoblastic leuke...

see more →

Patient Education  3 results see all →